Christopher Hite insider trades

Open-market stock purchases and sales by Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc, from SEC Form 4 filings since Jun 4, 2020.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +108%.

Recent trades

DateStockTradeValue
Sep 22, 2026RPRX Royalty Pharma plcSold$5.6M
Sep 22, 2026RPRX Royalty Pharma plcSold$231K
Aug 19, 2026RPRX Royalty Pharma plcSold (not open market)—
Aug 18, 2026RPRX Royalty Pharma plcSold$6M
Aug 5, 2026RPRX Royalty Pharma plcBought (not open market)—
Jun 23, 2026RPRX Royalty Pharma plcSold$1.8M
Jun 23, 2026RPRX Royalty Pharma plcSold$6.4M
May 6, 2026RPRX Royalty Pharma plcBought (not open market)—
Apr 16, 2026KLRA Kailera Therapeutics, IncBought (not open market)—
Mar 5, 2026VERA Vera Therapeutics, IncBought (not open market)—
Feb 11, 2026RPRX Royalty Pharma plcBought (not open market)—
Nov 5, 2025RPRX Royalty Pharma plcBought (not open market)—

Companies traded

  • RPRX Royalty Pharma plc: 1 buy, 6 sales, last Sep 22, 2026
  • KLRA Kailera Therapeutics, Inc: other filings, last Apr 16, 2026
  • VERA Vera Therapeutics, Inc: other filings, last Mar 5, 2026
  • XLRN Acceleron Pharma Inc: other filings, last Nov 19, 2021

Get free alerts when Christopher Hite files a new trade →